TD Waterhouse Canada Inc. Buys 739 Shares of Axon Enterprise, Inc $AXON

TD Waterhouse Canada Inc. grew its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 30.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,132 shares of the biotechnology company’s stock after purchasing an additional 739 shares during the period. TD Waterhouse Canada Inc.’s holdings in Axon Enterprise were worth $2,428,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in AXON. Wealthspire Advisors LLC raised its stake in Axon Enterprise by 15.2% during the 2nd quarter. Wealthspire Advisors LLC now owns 484 shares of the biotechnology company’s stock worth $401,000 after buying an additional 64 shares during the period. Perennial Investment Advisors LLC grew its stake in Axon Enterprise by 12.4% in the second quarter. Perennial Investment Advisors LLC now owns 918 shares of the biotechnology company’s stock valued at $760,000 after acquiring an additional 101 shares during the period. Purus Wealth Management LLC increased its holdings in shares of Axon Enterprise by 2.5% during the second quarter. Purus Wealth Management LLC now owns 2,196 shares of the biotechnology company’s stock valued at $1,818,000 after acquiring an additional 54 shares in the last quarter. Empowered Funds LLC raised its position in shares of Axon Enterprise by 804.6% during the second quarter. Empowered Funds LLC now owns 18,345 shares of the biotechnology company’s stock worth $15,189,000 after purchasing an additional 16,317 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Axon Enterprise by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock worth $7,399,515,000 after purchasing an additional 305,252 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Stock Performance

AXON stock opened at $521.99 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. The firm has a market cap of $41.19 billion, a PE ratio of 128.89, a P/E/G ratio of 29.49 and a beta of 1.45. The business has a 50 day moving average of $681.33 and a 200-day moving average of $731.06. Axon Enterprise, Inc has a 12-month low of $469.24 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.45 EPS. As a group, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AXON shares. Raymond James Financial restated an “outperform” rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Cowen reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Northland Securities set a $800.00 price target on shares of Axon Enterprise in a research report on Tuesday, August 5th. Craig Hallum upgraded Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a research note on Tuesday, August 5th. Finally, JMP Securities reissued a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research note on Monday, September 29th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $814.00.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director owned 1,416 shares of the company’s stock, valued at approximately $1,065,596.64. The trade was a 6.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Jennifer H. Mak sold 77 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the transaction, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 38,622 shares of company stock valued at $26,439,364 over the last quarter. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.